Genelux Corp

Genelux Corporation (NASDAQ: GNLX) is a late clinical-stage biotechnology company focused on improving the lives of patients affected by difficult-to-treat solid tumors. Their ChoiceTM Discovery Platform is the foundation of their oncolytic immunotherapy development, having produced over 500 different versions of the vaccinia virus. Olvi-Vec, their lead product candidate is currently in…More a Phase 3 registrational clinical trial for Platinum-Resistant/Refractory Ovarian Cancer (PRROC). Olvi-Vec is also being developed in Non-Small Cell Lung Cancer (NSCLC), recurrent Small Cell Lung Cancer (SCLC), and recurrent Ovarian Cancer. They are dedicated to advancing a pipeline of next-generation oncolytic immunotherapies that deliver the full complement of tumor neo-antigens with the power to stimulate a personalized immune response for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Information about their investigational products and clinical trials can be found here.